The GI Company, Inc. Release: Statistically Significant Phase II Clinical Results for Prophylactic Use of rhITF in Mucositis Published in Journal of Clinical Oncology
9/10/2009 11:10:41 AM
More...
|
The GI Company Reports Additional Phase II Clinical Data of Intestinal Trefoil Factor (rhITF) Oral Spray for Oral Mucositis
6/30/2008 8:41:40 AM
More...
|
The GI Company Reports Significant Reduction in Occurrence of Oral Mucositis in Phase II Study Presented at American Society of Clinical Oncology
6/3/2008 10:56:17 AM
More...
|
The GI Company Reports Significant Reduction in Occurrence of Oral Mucositis in Phase II Study; Abstract Posted Online at ASCO.org
5/16/2008 11:09:42 AM
More...
|
The GI Company to Present Phase I & II Oral Mucositis Data at MASCC/ISOO Annual Meeting
4/7/2008 10:27:53 AM
More...
|
The GI Company to Present Phase II Oral Mucositis Data at American Society of Clinical Oncology Annual Meeting
3/26/2008 8:57:12 AM
More...
|
The GI Company Expands Its Scientific Advisory Board
12/19/2007 8:42:30 AM
More...
|